Research programme: ovarian cancer small molecule therapeutics - BridGene Biosciences/Peter MacCallum Cancer Centre
Latest Information Update: 21 Dec 2021
At a glance
- Originator BridGene Biosciences; Peter MacCallum Cancer Centre
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ovarian cancer